Cassava Sciences | PTIE - Assets


Cassava Sciences reported $108.37M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Abbott USD 110.43B 23.72B Mar/2026
Amgen USD 95.64B 3.14B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cassava Sciences USD 108.37M 9.99M Mar/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Geron USD 519.01M 15.11M Jun/2026
J&J USD 201.06B 167M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Novavax USD 955.58M 87.59M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026